AmpliPhi Bio (NYSEMKT: APHB)
AmpliPhi Bio has been an interesting stock to watch so far today. Thanks to overwhelmingly strong pre-market activity, the stock started the day off well into the green. However, when the opening bell rang, it started making a run for the red. Below, we’ll talk about what we’re seeing from the stock, why, and what we’ll be watching for with regard to APHB ahead.
What We’re Seeing From APHB
As mentioned above, AmpliPhi Bio had a relatively strong start in the market today. As a result of strong pre-market activity, the stock found itself well into the green at the opening bell. However, since then, we’ve seen sharp declines, bringing it into the red. At the moment (10:15), APHB is trading at $0.50 per share after a loss of 0.60% thus far today.
Why The Stock Is On The Run
Early on this morning, we received a signal from Trade Ideas to keep an eye on APHB, and I’m glad we did. As soon as we got this signal, the CNA Finance team started digging to see exactly what was causing the movement. It didn’t take long to dig up the dirt in this case. The gains seem to be the result of positive data released from a clinical trial.
The clinical trial causing the movement was a Phase 1 clinical trial for which AmpliPhi Bio has released final results. The trial looked into AB-SA01 as a treatment targeting Staphylococcus aureus infections in patients with chronic rhinosinusitis.
In the data, we learned two great things. First and foremost, the study met its primary endpoints of safety and tolerability. On top of that, all 9 patients that were enrolled in the study experienced a reduction in the quantity of S. aureus infecting their sinuses. Some patients even showed complete eradication of the bacterial infection.
In a statement, M. Scott Salka, CEO at APHB, had the following to offer:
“We are delighted with the final results of this trial and are particularly encouraged that we saw a decrease in S. aureus bacterial load in all patients treated with AB-SA01… The fact that the patients enrolled in this study had all failed standard of care treatment, including previous sinus surgery, combined with compelling preclinical results in an animal model of CRS and these positive Phase 1 findings, gives us tremendous confidence in our decision to advance AB-SA01 into a Phase 2 trial in 2017.”
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will be keeping a close eye on APHB. In particular, we’re interested in following the progress associated with setting up the Phase 2 trial. We’ll keep a close eye on the news and bring it to you as it breaks.
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!
[Image Courtesy of Pixabay]